acute radiation syndrome


Also found in: Dictionary, Thesaurus, Acronyms, Encyclopedia, Wikipedia.

a·cute ra·di·a·tion syn·drome

a syndrome caused by exposure of the body to large amounts of radiation, (for example, from certain forms of therapy, accidents, and nuclear explosions). It is divided into three major forms that are, in ascending order of severity, the hematologic, gastrointestinal, and central nervous system-cardiovascular forms; its clinical manifestations are divided into prodromal, latent, overt, and recovery stages.

a·cute ra·di·a·tion syn·drome

(ARS) (ă-kyūt rādē-āshŭn sindrōm)
Disorder caused by exposure of the body to large amounts of radiation (e.g., from certain forms of therapy, accidents, and nuclear explosions).

a·cute ra·di·a·tion syn·drome

(ă-kyūt rādē-āshŭn sindrōm)
Syndrome caused by exposure of the body to large amounts of radiation; divided into three major forms that are, in ascending order of severity, the hematologic, gastrointestinal, and central nervous system-cardiovascular forms.
References in periodicals archive ?
It is also being developed, with funding by the US Government, as a medical countermeasure against chemical and radiological weapons, where its initial target indications are as a protective agent against the effects of acute radiation syndrome and delayed effects of acute radiation exposure.
Acute radiation syndrome occurs when the entire body is exposed.
1 million option to further advance the preclinical development of OrbeShield(TM) (oral beclomethasone 17,21-dipropionate), as a medical countermeasure (MCM) for the treatment of gastrointestinal acute radiation syndrome (GI ARS).
Contract Awarded for the advanced preclinical development of OrbeShield (oral beclomethasone 17,21-dipropionate or oral BDP) as a MCM for the treatment of gastrointestinal acute radiation syndrome (GI ARS)
Department of Defense (DoD) to develop BIO 300 as a new medical radiation countermeasure (MRC) for lethal exposure to radiation, also known as Acute Radiation Syndrome (ARS).
1 million to Soligenix to advance OrbeShield(TM) as a medical countermeasure (MCM) for the treatment of gastrointestinal acute radiation syndrome (GI ARS).
4 million under an option exercised by the Biomedical Advanced Research and Development Authority (BARDA) in the Office of the Assistant Secretary for Preparedness and Response of the Department of Health and Human Services, for the advanced development of CLT-008, a first-in-class, allogeneic, cell-based therapy for the treatment of Acute Radiation Syndrome (ARS).
Revenues included contracts with the US Department of Health and Human Service's Biomedical Advanced Research and Development Authority (BARDA) and the National Institute of Allergy and Infectious Diseases (NIAID) in support of OrbeShield(TM) (oral beclomethasone 17,21-dipropionate or BDP) development for the treatment of gastrointestinal acute radiation syndrome (GI ARS) and a contract with NIAID to advance the development of RiVax(TM), its proprietary ricin toxin vaccine, in conjunction with its heat stabilization technology, ThermoVax(TM), as a medical countermeasure to prevent the effects of ricin exposure.
7 million for our ricin toxin vaccine (RiVax(TM)) program utilizing our ThermoVax(TM) vaccine thermostablization platform, and adds to government contracts previously awarded for OrbeShield(TM) in gastrointestinal acute radiation syndrome (GI ARS) of up to $32.

Full browser ?